- Report
- October 2024
- 185 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 177 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- February 2025
- 215 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- October 2024
- 193 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 230 Pages
Global
From €2177EUR$2,290USD£1,829GBP
- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 130 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- August 2022
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- October 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- April 2018
- 195 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- December 2023
- 157 Pages
Global
€4749EUR$4,995USD£3,989GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
- Book
- July 2023
- 320 Pages

Raloxifene is a selective estrogen receptor modulator (SERM) used to treat and prevent breast cancer in postmenopausal women. It is also used to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis or who are at high risk for invasive breast cancer. Raloxifene works by blocking the effects of estrogen in breast tissue, which can help reduce the risk of breast cancer. It also helps to reduce the risk of fractures in postmenopausal women with osteoporosis.
Raloxifene is available in both oral and injectable forms. It is usually taken once a day, either with or without food. Common side effects of raloxifene include hot flashes, leg cramps, and joint pain.
Raloxifene is a widely used breast cancer drug, and is available from many pharmaceutical companies. Some of the companies that produce raloxifene include Pfizer, Novartis, and Mylan. Show Less Read more